Dextro-Naltrexone: The Opioid-Silent Mirror Image of Naltrexone

What the science actually shows, and what it doesn't, about (+)-naltrexone

Yoon Hang Kim, MD, MPH

Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician

About Dr. Kim

Yoon Hang Kim, MD, MPH, is board-certified in Preventive Medicine with more than 20 years of experience in integrative and functional medicine. He completed the University of Arizona Osher Fellowship under Dr. Andrew Weil and holds medical acupuncture certification through UCLA. His clinical focus includes low-dose naltrexone (LDN), autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome, MCAS, and mold toxicity. He is the author of eight books and more than 25 peer-reviewed articles.

Professional: www.yoonhangkim.com  |  Clinical: www.directintegrativecare.com

Important: Dextro-naltrexone is not available as a medication at this time. This article is for information only and is based on currently available research. It is not medical advice and is not a recommendation to obtain or use any product. Please talk with your own clinician about your health decisions.

Why this compound keeps coming up

If you work with low-dose naltrexone (LDN), sooner or later someone asks: "Isn't there a version that doesn't block opioids?" That question is where dextro-naltrexone, usually written (+)-naltrexone, enters the conversation.

It is a fascinating molecule. It is also an experimental research compound. It is not available as a medication at this time. It is not the same thing as prescribed LDN, and there is currently no established clinical use, approved product, or evidence-based human dosing regimen for it. This post walks through what it is, why researchers care, what the data really support, and where the hype gets ahead of the evidence.

What it is

Prescription naltrexone is the levo (active) form. It blocks classical opioid receptors, especially the mu-opioid receptor, and is FDA-approved for alcohol use disorder and relapse prevention in opioid use disorder.

Dextro-naltrexone is its mirror-image enantiomer. Same atoms, opposite three-dimensional arrangement. The appeal is straightforward: it appears to lack meaningful activity at classical opioid receptors, yet it retains effects in experimental immune and glial signaling systems. In theory, that could allow anti-neuroinflammatory or analgesic effects without blocking endogenous or therapeutic opioid analgesia.

The proposed mechanism

The leading hypothesis is that (+)-naltrexone interacts with the TLR4/MD-2 signaling complex, and possibly other innate-immune pathways. TLR4 signaling matters in activated microglia and in neuroimmune cytokine cascades. In preclinical pain models, inhibiting this pathway has been linked to less allodynia, less neuroinflammation, and reduced neurodegenerative signaling (1–5).

I would describe this mechanism cautiously, for four reasons:

• "Microglial inhibition" is shorthand, not a clinically validated, biomarker-defined mechanism in people.
• TLR4 pharmacology is complicated. It is context dependent and not limited to microglia in the CNS.
• Human cell data are suggestive only. Naltrexone can alter IL-6 and TNF-α responses to certain intracellular TLR stimuli in human immune cells (11), but that does not show that oral (+)-naltrexone treats inflammatory or neurologic disease.
• The LDN question remains open. The idea that LDN's clinical effects are mainly or reliably driven by TLR4/glial effects, rather than transient opioid-receptor blockade, is unproven.

What the studies show

Preclinical evidence

The rationale comes largely from in-vitro and animal work with opioid-inactive isomers of naloxone and naltrexone. Hutchinson and colleagues showed that (+)-naltrexone and (+)-naloxone act as TLR4 antagonists in vitro, and that they suppressed neuropathic pain in rats after sciatic nerve chronic constriction injury, with complete reversal during chronic infusion (5). Wang and colleagues later showed that (+)-naltrexone and (+)-naloxone inhibited LPS-induced TLR4 downstream signaling in cell systems, with reductions in TNF-α, nitric oxide, and reactive oxygen species (2). Proposed targets have included neuropathic pain, central sensitization, fatigue and cognitive symptom complexes, and neuroinflammatory disorders.

This is biologically interesting. But it is translational evidence, not clinical efficacy evidence.

Human evidence

Here the honest answer is short. The literature on dextro-naltrexone itself does not currently support therapeutic use in people. A detailed LDN review noted that dextro-naltrexone was not available for human use and that its authors knew of no human-subject studies (6). More recent plain-language summaries likewise describe it as not yet used in humans, discussing hoped-for future safety and efficacy work rather than completed trials.

That means we have no reliable data on:

• Indications
• Dose, titration, or formulation
• Pharmacokinetics and active metabolites in clients
• Drug–drug interactions
• Hepatic, reproductive, psychiatric, or long-term safety
• Whether it truly avoids opioid blockade at clinically relevant exposures
• Benefit compared with ordinary LDN, gabapentinoids, SNRIs, tricyclics, behavioral pain rehabilitation, or disease-specific treatment

How it relates to LDN

It is easy to blur these two, but they are not interchangeable.

LDN is ordinary naltrexone used off-label at doses far below those used for its approved indications. It still has opioid-receptor antagonism. It can precipitate withdrawal in opioid-dependent clients and interfere with opioid-containing analgesics, antidiarrheals, cough products, and perioperative opioid plans. Evidence for LDN in fibromyalgia, chronic pain, Crohn disease, MS-related symptoms, and post-viral syndromes is mixed and limited by small trials, observational designs, and inconsistent outcomes (7–10). For dosing guidance and detailed clinical evidence on LDN, see ifmsynergy.com.

Dextro-naltrexone is often pitched as a "better LDN," the idea being that it isolates the putative glial/TLR component without opioid antagonism. That is a hypothesis. It is not a demonstrated clinical advantage.

Clinical bottom line

• Do not treat dextro-naltrexone as an available LDN alternative. It is experimental and has no human clinical evidence base.
• A product labeled "dextro-naltrexone," "(+)-naltrexone," or "opioid-free naltrexone" should raise questions about provenance, identity, purity, sterility if injectable, and regulatory status.
• For clients who need opioid analgesia now, or may need it perioperatively, prescribed LDN itself calls for careful risk–benefit review and coordinated medication planning. Substituting an unvalidated compound is not evidence-based.
• The most defensible current role is as a preclinical pharmacology tool, not a client therapy.

A framing I find useful for client conversations: the compound helps scientists test whether naltrexone's non-opioid anti-inflammatory effects can be separated from opioid receptor blockade. It has not yet crossed the threshold into validated human treatment.

This article is informational only and reflects available research as of publication. Dextro-naltrexone is not available as a medication at this time. It does not replace individualized medical advice.

References

1. Hutchinson MR, Zhang Y, Shridhar M, et al. Evidence that opioids may have toll-like receptor 4 and MD-2 effects. Brain Behav Immun. 2010;24(1):83–95. doi:10.1016/j.bbi.2009.08.004.

2. Wang X, et al. Naltrexone and (+)-naloxone as antagonists of toll-like receptor 4. Brain Behav Immun. 2016;50:159–170.

3. Hutchinson MR, Shavit Y, Grace PM, Rice KC, Maier SF, Watkins LR. Exploring the neuroimmunopharmacology of opioids: an integrative review of mechanisms of central immune signaling and their implications for opioid analgesia. Pharmacol Rev. 2011;63(3):772–810. doi:10.1124/pr.110.004135.

4. Hutchinson MR, Northcutt AL, Hiranita T, et al. Opioid activation of toll-like receptor 4 contributes to drug reinforcement. J Neurosci. 2012;32(33):11187–11200. doi:10.1523/JNEUROSCI.0684-12.2012.

5. Hutchinson MR, Zhang Y, Brown K, et al. Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4). Eur J Neurosci. 2008;28(1):20–29.

6. Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014;33(4):451–459. doi:10.1007/s10067-014-2517-2. PMID: 24526250.

7. Younger J, Noor N, McCue R, Mackey S. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis Rheum. 2013;65(2):529–538. doi:10.1002/art.37734.

8. Parkitny L, Younger J. Reduced pro-inflammatory cytokines after eight weeks of low-dose naltrexone for fibromyalgia. Biomedicines. 2017;5(2):16. doi:10.3390/biomedicines5020016.

9. Toljan K, Vrooman B. Low-dose naltrexone (LDN)—review of therapeutic utilization. Med Sci (Basel). 2018;6(4):82. doi:10.3390/medsci6040082.

10. Patten DK, Schultz BG, Berlau DJ. The safety and efficacy of low-dose naltrexone in the management of chronic pain and inflammation in multiple sclerosis, fibromyalgia, Crohn's disease, and other chronic pain disorders. Pharmacotherapy. 2018;38(3):382–389. doi:10.1002/phar.2086.

11. Cant R, Dalgleish AG, Allen RL. Naltrexone inhibits IL-6 and TNF-α production in human immune cell subsets following stimulation with ligands for intracellular Toll-like receptors. Front Immunol. 2017;8:809. doi:10.3389/fimmu.2017.00809.

Yoon Hang Kim, MD, MPH is the author of MCAS: Epidemic in Plain Sight and LDN Primer, both available on Amazon, and the founder of the LDN Support Group.

Professional: www.yoonhangkim.com  |  Clinical: www.directintegrativecare.com